Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Cancer Med. 2023 Jun;12(12):13309-13318. doi: 10.1002/cam4.6029. Epub 2023 May 6.
Neoadjuvant chemotherapy (nCT) appears in a few clinical studies as an alternative to neoadjuvant chemoradiation (nCRT) in selected patients with locally advanced rectal cancer (LARC). We aimed to compare the clinical outcomes of nCT with or without nCRT in patients with LARC and to identify patients who may be suitable for nCT alone.
A total of 155 patients with LARC who received neoadjuvant treatment (NT) were retrospectively analysed from January 2016 to June 2021. The patients were divided into two groups: nCRT (n = 101) and nCT (n = 54). More patients with locally advanced disease (cT4, cN+ and magnetic resonance imaging-detected mesorectal fascia [mrMRF] positive [+]) were found in the nCRT group. Patients in the nCRT group received a dose of 50 Gy/25 Fx irradiation with concurrent capecitabine, and the median number of nCT cycles was two. In the nCT group, the median number of cycles was four.
The median follow-up duration was 30 months. The pathologic complete response (pCR) rate in the nCRT group was significantly higher than that in the nCT group (17.5% vs. 5.6%, p = 0.047). A significant difference was observed in the locoregional recurrence rate (LRR); 6.9% in the nCRT group and 16.7% in the nCT group (p = 0.011). Among patients with initial mrMRF (+) status, the LRR in the nCRT group was significantly lower than that in the nCT group (6.1% vs. 20%, p = 0.007), but not in patients with initial mrMRF negative (-) (10.5% in each group, p = 0.647). Compared with the nCT group, a lower LRR was observed in patients in the nCRT group with initial mrMRF (+) converted to mrMRF (-) after NT (5.3% vs. 23%, p = 0.009). No significant difference was observed between the two groups regarding acute toxicity and overall and progression-free survivals. Multivariate analysis showed that nCRT and ypN stage were independent prognostic factors for the development of LRR.
Patients with initial mrMRF (-) may be suitable for nCT alone. However, patients with initial mrMRF (+) converted to mrMRF (-) after nCT are still at high risk of LRR, and radiotherapy is recommended. Prospective studies are required to confirm these findings.
新辅助化疗(nCT)在少数临床研究中被视为局部晚期直肠癌(LARC)患者新辅助放化疗(nCRT)的替代方案。本研究旨在比较 LARC 患者接受 nCT 或 nCRT 的临床结局,并确定可能适合单纯 nCT 的患者。
回顾性分析 2016 年 1 月至 2021 年 6 月期间接受新辅助治疗(NT)的 155 例 LARC 患者的临床资料。将患者分为两组:nCRT 组(n=101)和 nCT 组(n=54)。nCRT 组中更多患者存在局部晚期疾病(cT4、cN+和磁共振成像检测到的中肠筋膜[mrMRF]阳性[+])。nCRT 组患者接受 50Gy/25Fx 照射联合卡培他滨治疗,nCT 周期中位数为 2 个周期。nCT 组中,nCT 周期的中位数为 4 个周期。
中位随访时间为 30 个月。nCRT 组的病理完全缓解(pCR)率显著高于 nCT 组(17.5% vs. 5.6%,p=0.047)。局部区域复发率(LRR)也存在显著差异,nCRT 组为 6.9%,nCT 组为 16.7%(p=0.011)。在初始 mrMRF(+)状态的患者中,nCRT 组的 LRR 显著低于 nCT 组(6.1% vs. 20%,p=0.007),但在初始 mrMRF(-)的患者中则无显著差异(两组均为 10.5%,p=0.647)。与 nCT 组相比,nCRT 组初始 mrMRF(+)经 NT 后转为 mrMRF(-)的患者 LRR 较低(5.3% vs. 23%,p=0.009)。两组的急性毒性、总生存期和无进展生存期无显著差异。多因素分析显示,nCRT 和 ypN 分期是 LRR 发生的独立预后因素。
初始 mrMRF(-)的患者可能适合单纯 nCT。然而,初始 mrMRF(+)经 nCT 后转为 mrMRF(-)的患者 LRR 仍处于高危状态,建议行放疗。需要前瞻性研究来证实这些发现。